Improving life for cancer patients through transformative drugs




First patient with colorectal cancer dosed in the Phase ll study of birinapant in combination with Keytruda®

Read more

The transformation into a company focused on clinical development of pharmaceuticals has now been completed and Medivir gives a project update

Read more

Medivir nominates MIV-828 as a candidate drug for the treatment of hematological malignancies

Read more

Partner with Medivir

Partnering is an important element of our business strategy. Together with our partners we have been successful in taking two products from research, through clinical development to launch on a global scale.